Demystify Meds for Moderate to Severe Crohn’s Disease

August 2023

There’s a growing number of meds for Crohn’s disease...especially now that upadacitinib (Rinvoq) is in the mix.

This “Janus kinase (JAK) inhibitor” is already approved for rheumatoid arthritis...ulcerative colitis...and other conditions.

Now upadacitinib is the first oral once-daily med indicated for moderate to severe Crohn’s disease.

Practical advice for a better career, with unlimited access to CE

Hospital Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Shortages Check Imported Meds for Important Differences
Cultural Awareness Use Inclusive Language to Reduce Stigma
Adverse Events Be Ready for Lipid Rescue in Drug Toxicity
Crohn's Disease Demystify Meds for Moderate to Severe Crohn’s Disease
Practice Work as a Team to Make IV-to-PO Conversions
Nausea & Vomiting Ensure Surgery Patients Get Antiemetics at the Right Times
Med Safety Support Safe Use of Stimulants
Menopause Watch for Fezolinetant, a New Rx for Hot Flashes
NatMed Spotlight Be Prepared With Answers About Milk Thistle